[April 17, 2015]

Research and Markets: Global Cancer Monoclonal Antibody Partnering 2010-2015: Deal Trends, players, financials and forecasts

Research and Markets (http://www.researchandmarkets.com/research/b6lps2/global_cancer) has announced the addition of the "Global Cancer Monoclonal Antibody Partnering 2010-2015: Deal Trends, players, financials and forecasts" report to their offering.

The Global Cancer Monoclonal Antibody Partnering 2010-2015: Deal trends, players, financials and forecasts report provides an understanding and access to the cancer monoclonal antibody partnering deals and agreements entered into by the worlds leading healthcare companies.

The Global Cancer Monoclonal Antibody Partnering 2010-2015: Deal trends, players, financials and forecasts report provides an understanding and access to the cancer monoclonal antibody partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides an understanding and analysisof how and why companies enter cancer monoclonal antibody partnering deals. The majority of deals are discovery stage whereby the licensee obtains a right or an option right to license the licensors monoclonal antibody technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

companies worldwide.

Global Cancer Monoclonal Antibody Partnering 2010-2015: Deal trends, players, financials and forecasts includes:

• Trends in cancer monoclonal antibody dealmaking in the biopharma industry since 2009
• Analysis of cancer monoclonal antibody deal structure
• Access to headline, upfront, milestone and royalty data
• Access to over 250 cancer monoclonal antibody deal records
• The leading cancer monoclonal antibody deals by value since 2009

In Global Cancer Monoclonal Antibody Partnering 2010-2015: Deal trends, players, financials and forecasts, the available deals are listed by:

• Company A-Z
• Headline value
• Stage of development at signing
• Deal component type
• Specific oncology therapy target
• Monoclonal antibody type

Key Topics Covered:

Chapter 1 - Introduction

Chapter 2 - Trends in cancer monoclonal antibody dealmaking

Chapter 3 - Average financial deal terms for cancer monoclonal antibody partnering

Chapter 4 - Leading cancer monoclonal antibody deals

Chapter 5 - Cancer monoclonal antibody contracts directory

Chapter 6 - Future trends and companies in cancer monoclonal antibody deal making

Chapter 7 - Partnering resource centre

For more information visit http://www.researchandmarkets.com/research/b6lps2/global_cancer

[ Back To TMCnet.com's Homepage ]